scPharmaceuticals الأرباح الموزعة 2024

ماذا يفعل scPharmaceuticals؟

scPharmaceuticals Inc is a US pharmaceutical company based in Lexington, Massachusetts. The company was founded in 2013 and currently employs over 100 staff members. It specializes in the development and marketing of innovative drugs for chronic diseases. The company's business model focuses on the development of drugs in the areas of cardiovascular, renal function, and infectious diseases. The goal is to provide better treatment options for patients suffering from chronic diseases than current therapies. The company relies on innovative technologies to improve the effectiveness and tolerability of the developed medications. One of scPharmaceuticals' core areas is cardiovascular therapy. The company is working on the development of a drug called Furoscix™ for the treatment of patients with acute heart failure. Furoscix™ is a convenient, portable infusion system that allows patients to receive the medication at home or in an outpatient facility instead of staying in a hospital. Currently, Furoscix™ is in Phase 3 clinical trials, and results are still pending. Another core area for scPharmaceuticals is kidney therapy. The company is developing a drug called SC-001 for the treatment of patients with chronic kidney insufficiency. SC-001 is a novel medication based on innovative technology that allows the body to break down the drug more slowly, leading to a longer duration of action. Together with other products, such as a midazolam nasal spray for sedation during endoscopies or a fentanyl nasal spray for pain management after surgeries, scPharmaceuticals is working to revolutionize drug therapy and improve patients' quality of life. The company's history is marked by various stages of development. In 2014, scPharmaceuticals received funding of $16.8 million from various investors, including venture capital firms and strategic partners from the pharmaceutical and biotech industry. In 2018, the company went public on the Nasdaq stock exchange and sold shares worth approximately $90 million. These financings enabled the clinical development and future marketing of Furoscix™ and other medications. scPharmaceuticals aims to develop innovative solutions for patients with chronic diseases and provide better treatment options. The company works closely with physicians, hospitals, and patient groups to understand and cater to the needs of its user groups. With advanced technology and the latest medical knowledge, scPharmaceuticals is working to develop the medications of the future. scPharmaceuticals هو واحد من الشركات الأكثر شعبية على Eulerpool.com.